1. Akalu YT, Rothlin CV, Ghosh S. (2017) TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev, 276 (1): 165-177. [PMID:28258690]
2. Baladi T, Abet V, Piguel S. (2015) State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist. Eur J Med Chem, 105: 220-37. [PMID:26498569]
3. Caberoy NB, Alvarado G, Bigcas JL, Li W. (2012) Galectin-3 is a new MerTK-specific eat-me signal. J Cell Physiol, 227 (2): 401-7. [PMID:21792939]
4. Caberoy NB, Zhou Y, Li W. (2010) Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis. EMBO J, 29 (23): 3898-910. [PMID:20978472]
5. Davra V, Kimani SG, Calianese D, Birge RB. (2016) Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response. Cancers (Basel), 8 (12). [PMID:27916840]
6. Lu Q, Lemke G. (2001) Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science, 293 (5528): 306-11. [PMID:11452127]
7. Moody G, Belmontes B, Masterman S, Wang W, King C, Murawsky C, Tsuruda T, Liu S, Radinsky R, Beltran PJ. (2016) Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo. Int J Cancer, 139 (6): 1340-9. [PMID:27170265]
8. Paolino M, Penninger JM. (2016) The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy. Cancers (Basel), 8 (10). [PMID:27775650]
9. Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S. (2015) TAM receptor signaling in immune homeostasis. Annu Rev Immunol, 33: 355-91. [PMID:25594431]
To cite this family introduction, please use the following:
Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family, introduction. Last modified on 13/03/2018. Accessed on 02/11/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/FamilyIntroductionForward?familyId=328.